



Q3 FY2023 Earnings

April 27, 2023

Presentation of financial information & forward-looking statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.


This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed’s current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue”, or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the “Risk Factors” identified in ResMed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

Our mission is to change 250 million lives in 2025

We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice




*During the last 12 months, we changed over **156 million lives*** with our digital health products and cloud-based software solutions*


ResMed | The global leader in connected and digital health

Key Statistics¹

Headquarters	San Diego, CA
Founded	1989
LTM 3Q23 revenue	\$4.0B
Listed (NYSE, ASX)	1995, RMD
Market cap ²	~\$35B
Countries served	140+
Total employees	>10,000



- Devices
- Masks & Other
- OOH SaaS



- U.S., Canada, and Latin America
- Europe, Asia, and Other
- OOH SaaS (U.S. & Germany)

Our businesses

Sleep Apnea

Delivering a market-leading patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes by leveraging global digital health solutions

Respiratory Care

Improving the lives of patients with COPD, asthma, and other key chronic respiratory diseases on their healthcare journey – lowering costs, preventing hospitalization, and creating end-to-end care solutions

Software as a Service (SaaS)

Providing a network out-of-hospital healthcare SaaS management solutions that help providers deliver more personalized care, measurable results, and improved health outcomes across large populations

¹As of 3/31/23

²As of 4/27/23, date of Q3 2023 earnings

ResMed 2025: a patient-centric, digitally-enabled strategy




250 million lives improved
in out-of-hospital healthcare
in 2025!

Purpose • Empower people to live **happier, healthier,**
and **higher quality lives** in the comfort of
their home


Growth Focus • Global health epidemics in **sleep apnea,**
COPD, other major chronic conditions,
and **SaaS** solutions that improve care in
out-of-hospital settings

Growth Advantage • Transform care through **innovative solutions** and
tech-driven integrated care to drive superior
outcomes, experiences, and efficiency

Growth Foundations • High-performing, diverse, and entrepreneurial people
• Industry-leading innovation and business excellence
• Digital health technology and scientific leadership



Priorities that guide our daily focus



Grow and differentiate our core sleep apnea, COPD, and asthma businesses across global markets

Deliver world-leading medical devices and digital health technology to engage physicians, providers, and patients

Build the world's best software solutions network for healthcare that is delivered outside the hospital

Our triple aim:

- I. Slow chronic disease progression
- II. Reduce overall healthcare system costs
- III. Improve the quality of life for the patient


Empower people to live happier, healthier, and higher quality lives in the comfort of their homes

Financial Results




Q3 FY23 financial results


Revenue by Business
Q3 FY23



Revenue by Region
Q3 FY23




Revenue (\$M)



Non-GAAP Operating
Income (\$M)




Non-GAAP EPS



NOTE: See reconciliation to GAAP in Appendix

Solid balance sheet

Total debt outstanding	\$1,586M
Less: Cash & cash equiv.	\$228M
Net Debt	\$1,358M
Unused borrowing capacity	\$605M




Expect liquidity to improve as supply chain environment improves and inventory levels come down

Track record of strong financial returns for shareholders

(Financial data as of March 31, 2023)


Revenue (\$B)

12% CAGR



Non-GAAP Operating Income (\$M)

15% CAGR



Non-GAAP EPS

14% CAGR



Total shareholder return, TSR (NYSE shares as of March 31, 2023): **1-yr (9)%** | **3-yr 52%** | **5-yr 134%**


NOTE: See reconciliation to GAAP in Appendix

10 © 2023 ResMed | Q3 2023 Earnings Presentation – Apr. 27, 2023



Strategic capital allocation framework

Capital deployed over last 3 years
(through March 31, 2023)



- Reinvest in R&D
- M&A
- Dividends
- Share repurchase ^(A)

Strategic
Growth
Priorities

Capital
Returns to
Shareholders

Reinvest for
growth

- Reinvest in product development for high-return organic growth
- 7-8% of revenue invested in R&D

Pursue M&A

- Actively evaluate potential acquisitions
- Pursue targets aligned with long-term strategic goals and financial objectives

Support dividends

- Regular return of cash to shareholders through dividend at a level that is meaningful and sustained

Opportunistically
repurchase shares

- Opportunistic repurchase of shares
- Current program suspended following recent acquisitions

Disciplined focus on ROIC and delivering total return

(A): ResMed has not repurchased shares during the 3-year period ended March 31, 2023

Driving long-term shareholder value



Growth & Innovation

- Global leader in digital health for sleep and respiratory care
- Long-term growth opportunities
- 9,500+ patents and designs
- 7-8% of revenue invested in R&D



Market Dynamics

- Underpenetrated markets in sleep and COPD
- Healthcare costs continue to increase
- Focus on improving patient outcomes
- Value-based technology solutions



Financial Results

- Historical revenue and profit growth
- Recurring revenue
- Operating excellence program
- Strong track record of disciplined capital deployment

ResMed is the global leader in connected & digital health

Contact Investor Relations

Phone: (858) 836-5971

Email: investorrelations@resmed.com

Website: investor.resmed.com

APPENDIX



Reconciliation of non-GAAP financial measures

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:

(Unaudited; \$ in thousands, except for per share amounts)

	Three Months Ended		Nine Months Ended	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
Revenue	\$ 1,116,898	\$ 864,500	\$ 3,100,936	\$ 2,663,390
GAAP cost of sales	\$ 499,146	\$ 373,303	\$ 1,362,661	\$ 1,161,585
Less: Amortization of acquired intangibles ^(A)	(8,322)	(10,982)	(22,001)	(33,271)
Non-GAAP cost of sales	\$ 490,824	\$ 362,321	\$ 1,340,660	\$ 1,128,314
GAAP gross profit	\$ 617,752	\$ 491,197	\$ 1,738,275	\$ 1,501,805
GAAP gross margin	55.3 %	56.8 %	56.1 %	56.4 %
Non-GAAP gross profit	\$ 626,074	\$ 502,179	\$ 1,760,276	\$ 1,535,076
Non-GAAP gross margin	56.1 %	58.1 %	56.8 %	57.6 %

Note regarding non-GAAP reconciliations

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition related expenses and the reserve for disputed tax positions from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Reconciliation of non-GAAP financial measures, cont'd

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

(Unaudited; \$ in thousands, except for per share amounts)

	Three Months Ended		Nine Months Ended	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
GAAP income from operations	\$ 300,671	\$ 234,265	\$ 856,602	\$ 744,889
Amortization of acquired intangibles—cost of sales ^(A)	8,322	10,982	22,001	33,271
Amortization of acquired intangibles—operating expenses ^(A)	12,188	7,730	29,701	23,175
Acquisition-related expenses ^(A)	—	—	9,157	—
Non-GAAP income from operations	<u>\$ 321,181</u>	<u>\$ 252,977</u>	<u>\$ 917,461</u>	<u>\$ 801,335</u>

Note regarding non-GAAP reconciliations

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition related expenses and the reserve for disputed tax positions from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Reconciliation of non-GAAP financial measures, cont'd

The measure “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

(Unaudited; \$ in thousands, except for per share amounts)

	Three Months Ended		Nine Months Ended	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
GAAP net income	\$ 232,500	\$ 179,012	\$ 667,892	\$ 584,376
Amortization of acquired intangibles—cost of sales, net of tax ^(A)	6,207	8,374	16,531	25,373
Amortization of acquired intangibles—operating expenses, net of tax ^(A)	9,090	5,894	22,317	17,673
Acquisition related expenses, net of tax ^(A)	—	—	7,527	—
Reserve for disputed tax position ^(A)	—	—	—	4,111
Non-GAAP net income ^(A)	<u>\$ 247,797</u>	<u>\$ 193,280</u>	<u>\$ 714,267</u>	<u>\$ 631,533</u>
GAAP diluted shares outstanding	147,395	146,962	147,400	147,034
GAAP diluted earnings per share	\$ 1.58	\$ 1.22	\$ 4.53	\$ 3.97
Non-GAAP diluted earnings per share ^(A)	\$ 1.68	\$ 1.32	\$ 4.85	\$ 4.30

Note regarding non-GAAP reconciliations

(A) ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition related expenses and the reserve for disputed tax positions from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.